DELAYED INTESTINAL-ABSORPTION OF LEVOTHYROXINE

被引:109
作者
BENVENGA, S [1 ]
BARTOLONE, L [1 ]
SQUADRITO, S [1 ]
GIUDICE, FL [1 ]
TRIMARCHI, F [1 ]
机构
[1] UNIV MESSINA,SERV AUTONOMO ENDOCRINOL,I-98125 MESSINA,ITALY
关键词
D O I
10.1089/thy.1995.5.249
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
We report four female patients with nodular goiter (in two of the four due to Hashimoto's thyroidits) and one male patient with frank hypothyroidism due to Hashimoto's thyroiditis in whom TSH-suppressive or replacement L-T-4 therapy failed to suppress or, respectively, normalize serum TSH. As is typical in our country, our patients took L-T-4 15-20 min before a light breakfast, Gastrointestinal or other diseases and drugs known to interfere with the intestinal absorption of L-T-4 were not the cause of this failure, The gastrointestinal absorption test of L-T-4 (1000 mu g) was performed in four patients; in three patients it revealed peculiar abnormalities in that (i) the absorption peak was >70% but occurred at 4 hr vs an average of 2 hr in 12 euthyroid controls (EC) and 3 hr in 10 primary hypothyroid controls (HC); (ii) 50% of the maximal absorption occurred at 110 min vs 45 min in EC and 50 min in HC; (iii) the maximal increment in T-4 absorption was between 90 and 120 min (+111%) vs between 30 and 60 min in EC (+312%) and HC (+354%), In sum, only the first part of the absorption curve of T-4 was shifted to the right (in three of the four women) and this shift was more pronounced and extended to the second part of the curve in the fourth patient; in this last patient absorption peak was 44% at 180 min, Based on these results, we obtained full suppression or normalization of TSH by postponing breakfast for at least 60 min after T-4 ingestion. The precise cause for the ''inertia'' in the early phase of T-4 absorption is not known, but since it was observed in two patients with euthyroid nodular goiter, it is not associated with hypothyroidism per se.
引用
收藏
页码:249 / 253
页数:5
相关论文
共 16 条
  • [1] PSEUDOMALABSORPTION OF LEVOTHYROXINE
    AIN, KB
    REFETOFF, S
    FEIN, HG
    WEINTRAUB, BD
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1991, 266 (15): : 2118 - 2120
  • [2] BERG JA, 1992, J CLIN PHARMACOL, V32, P1135
  • [3] BLOUIN RA, 1989, CLIN PHARMACY, V8, P588
  • [4] CARNELL NE, 1994, CURRENT THERAPY ENDO, P82
  • [5] EDDY RL, 1994, 76TH ANN M END SOC A
  • [6] GEATTI O, 1993, THYROIDOL CLIN EXP, V5, P597
  • [7] GREENSTADT MA, 1982, HORMONE DRUGS, P537
  • [8] Hays M T, 1991, Thyroid, V1, P241, DOI 10.1089/thy.1991.1.241
  • [9] ABSORPTION OF ORAL THYROXINE IN MAN
    HAYS, MT
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1968, 28 (06) : 749 - +
  • [10] HAYS MT, 1989, THYROID TODAY, V12, P1